Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture P...
April 19 2021 - 8:00AM
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq:
ZIOP), announced today that in March, the first patient was infused
in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T
Phase I Trial, being conducted by Eden BioCell, its joint venture
with TriArm Therapeutics.
The patient was treated at National Taiwan
University Hospital under the direction of lead investigator, Dr.
Shang-Ju Wu.
The patient’s T cells, collected from the
patient via apheresis, were genetically engineered utilizing the
Company’s non-viral Sleeping Beauty transposon transposase system
and infused two days after gene transfer.
“We are excited to be conducting this important
trial for this experimental treatment,” said Dr. Jay Zhang, Chief
Executive Officer of TriArm Therapeutics.
The Company and Eden BioCell will provide
updates regarding the experimental treatment and other patient data
in the second half of the year at appropriate venue(s), including
scientific conferences, publications and / or bespoke events that
the Company may convene.
About the Trial
“Infusion of CD19-Specific Chimeric Antigen Receptor
T-cells Produced by Rapid Personalized Manufacture for Patients
with Advanced Lymphoid Malignancies”This is a single
center phase I, open-label dose-escalation trial, for patients with
relapsed CD19+ leukemias and lymphomas. Up to 24 patients will be
enrolled in this trial. The primary endpoint of the trial is to
evaluate the safety and tolerability of autologous CD19-specific T
cells manufactured using the RPM process.
About Ziopharm Oncology,
Inc.Ziopharm is developing non-viral and cytokine-driven
cell and gene therapies that weaponize the body’s immune system to
treat the millions of people globally diagnosed with cancer each
year. With its multiplatform approach, Ziopharm is at the forefront
of immuno-oncology. Ziopharm’s pipeline is built for commercially
scalable, cost effective T-cell receptor T-cell therapies based on
its non-viral Sleeping Beauty gene transfer platform, a
rapidly manufactured Sleeping Beauty-enabled CD19-specific
CAR-T program, and a precisely controlled IL-12 gene therapy. The
Company has clinical and strategic collaborations with
the National Cancer Institute, The University of Texas MD
Anderson Cancer Center and Regeneron Pharmaceuticals. For more
information, please visit www.ziopharm.com.
About Eden BioCellIn December 2018, Ziopharm
and TriArm Therapeutics announced the launch of Eden BioCell to
lead clinical development and commercialization of Ziopharm’s RPM
Sleeping Beauty-generated CAR-T therapies in Greater China and
Korea.
About TriArm TherapeuticsTriArm Therapeutics is
a cell therapy company with R&D operations in Germany, United
States and Asia. The company is dedicated to the treatment of
cancer and autoimmune diseases.
Investor Relations Contact:Adam D. Levy, Ph.D.,
MBAEVP, Investor Relations and Corporate CommunicationsT:
508.552.9255E: alevy@ziopharm.com
Forward-Looking Statements DisclaimerThis press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts, and in some cases can be identified by terms such as "may,"
"will," "could," "expects," "plans," "anticipates," and "believes."
These statements include, but are not limited to, statements
regarding the number of patients to be enrolled, and the timing of
updates for, Eden BioCell’s CAR-T Phase I trial. Although
Ziopharm’s management team believes that the expectations reflected
in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Ziopharm,
that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and
uncertainties include among other things, changes in Eden BioCell’s
operating plans that may impact its cash expenditures, the
uncertainties inherent in research and development, future clinical
data and analysis; the strength and enforceability of Ziopharm’s
intellectual property rights; competition from other pharmaceutical
and biotechnology companies as well as risk factors discussed or
identified in the public filings with the Securities and
Exchange Commission made by Ziopharm, including those risks
and uncertainties listed in Ziopharm’s Quarterly Report on Form
10-Q filed by Ziopharm with the Securities and Exchange
Commission. We are providing this information as of the date of
this press release, and Ziopharm does not undertake any obligation
to update or revise the information contained in this press release
whether as a result of new information, future events or any other
reason.
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Apr 2024 to May 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From May 2023 to May 2024